Drug Trial Radar · NCT07213583
Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM
Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
35
Planned (sponsor's estimate)
Start
Aug 28, 2025
Primary completion
Oct 31, 2026
Study completion Oct 31, 2026
Sponsor
- Lead sponsor
- Neurimmune AGIndustry
- Sponsor type
- Industry
- Collaborators
- Alexion Pharmaceuticals, Inc.
- First posted
- Oct 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, single-arm, multicenter study to evaluate the pharmacodynamics and safety of re-treatment with ALXN2220 in previous participants of Study NI006-101.
Conditions
- Amyloid Transthyretin Cardiomyopathy
Interventions
ALXN2220Drug
Participants will receive ALXN2220 via IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline to Week 48 in ECV measured by cMRITime frame: Baseline, Week 48
- Change from Baseline to Week 48 in Heart Retention/Whole Body Retention measured by scintigraphyTime frame: Baseline, Week 48
Locations
6 sites in 4 countries. Site status is shown where the registry gives one.
Hôpital Henri Mondor
Créteil, France
CHU de Rennes - Hôpital Pontchaillou
Rennes, France
CHU Toulouse - Hôpital Rangueil
Toulouse, France
Universitätsklinikum Heidelberg
Heidelberg, Germany
University Medical Center Groningen
Groningen, Netherlands
Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.